1096.2000 -7.10 (-0.64%)
NSE Sep 23, 2025 15:25 PM
Volume: 27,490
 

1096.20
-0.64%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs
More from Tatva Chintan Pharma Chem Ltd.
Recommended